Polymeric Core-Shell Combinatorial Nanomedicine for Synergistic Anticancer Therapy

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Core-shell nanostructures offer potential for combination drug delivery but face challenges in synthesis, stability, and biocompatibility.
• Developing stable and effective nanocarriers is crucial for advancing combination cancer therapy.

Purpose of the Study:

• To develop a simple, one-step synthesis of a stable carboxymethyl chitosan-coated poly(lactide-co-glycolide) (cmcPLGA) core-shell nanostructure for dual-drug delivery.
• To evaluate the efficacy of this nanostructure for co-delivering docetaxel (Dtxl) and doxorubicin (Dox) in a cancer-mimicked environment.

Main Methods:

• A one-step nanoprecipitation self-assembly process was used to create cmcPLGA core-shell nanostructures.
• Docetaxel (Dtxl) was loaded into the core and doxorubicin (Dox) into the shell.
• The pH-responsive behavior and drug release kinetics were analyzed.
• The cytotoxicity and synergistic effects of the dual-drug formulation were evaluated on BT549, PC3, and A549 cancer cell lines.

Main Results:

• The cmcPLGA nanostructures demonstrated compartmentalized loading of Dtxl (~2.06%) and Dox (~1.2%) at a clinically relevant 1.7:1 weight ratio.
• The nanoparticles exhibited pH-responsive behavior, with ζ-potential shifting from -13 mV at pH 7.4 to -2 mV at pH 6, facilitating tumor accumulation and on-site drug release.
• Sequential release of Dox followed by Dtxl was achieved.
• The dual-drug formulation showed significantly enhanced growth inhibition and synergistic effects (Combination Index: 0.2-0.3) against multiple cancer cell lines compared to single-drug treatments.
• The mechanism involved G2/M phase arrest and apoptosis.

Conclusions:

• The developed cmcPLGA core-shell nanostructure provides a simple and effective platform for combination drug delivery.
• The pH-responsive, sequentially releasing dual-drug formulation exhibits significant synergistic anticancer activity, highlighting its potential for improved cancer therapy.